Insulet Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Insulet stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PODD, but not buy additional shares or sell existing shares.
View analyst ratings for Insulet or view top-rated stocks.

Wall Street analysts have given Insulet a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Insulet wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Insulet.

Insulet Co. (NASDAQ:PODD) issued its earnings results on Monday, February, 22nd. The medical instruments supplier reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.22. The medical instruments supplier had revenue of $246.10 million for the quarter, compared to analyst estimates of $232.89 million. Insulet had a trailing twelve-month return on equity of 1.52% and a net margin of 0.93%. The firm's revenue for the quarter was up 17.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.08 EPS.
View Insulet's earnings history.

Insulet's stock was trading at $172.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PODD stock has increased by 63.0% and is now trading at $280.55.
View which stocks have been most impacted by COVID-19.

Insulet issued an update on its second quarter 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $248.93 million-$257.98 million, compared to the consensus revenue estimate of $261.09 million.

15 brokers have issued 1 year price objectives for Insulet's stock. Their forecasts range from $230.00 to $300.00. On average, they anticipate Insulet's share price to reach $266.43 in the next year. This suggests that the stock has a possible downside of 5.0%.
View analysts' price targets for Insulet or view top-rated stocks among Wall Street analysts.

61 employees have rated Insulet CEO Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among Insulet's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), Baxter International (BAX), DexCom (DXCM), ResMed (RMD), Teleflex (TFX), STERIS (STE), Hologic (HOLX) and Abiomed (ABMD).
View all of PODD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Square (SQ), The Walt Disney (DIS), salesforce.com (CRM), Roku (ROKU) and The Trade Desk (TTD).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by many different retail and institutional investors. Top institutional shareholders include Primecap Management Co. CA (2.29%), Fred Alger Management LLC (1.68%), Viking Global Investors LP (1.56%), Coatue Management LLC (1.46%), Clearbridge Investments LLC (1.27%) and William Blair Investment Management LLC (1.20%). Company insiders that own Insulet stock include Bret Christensen, Charles Alpuche, Corinne H Nevinny, David A Lemoine, Eric Benjamin, John A Fallon, Michael P Spears, Sally Crawford and Shacey Petrovic.
View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Coatue Management LLC, Capital International Investors, Clearbridge Investments LLC, Primecap Management Co. CA, William Blair Investment Management LLC, UBS Group AG, and Janus Henderson Group PLC. Company insiders that have sold Insulet company stock in the last year include Bret Christensen, Charles Alpuche, Eric Benjamin, John A Fallon, Sally Crawford, and Shacey Petrovic.
View insider buying and selling activity for Insulet or view top insider-selling stocks.

PODD stock was bought by a variety of institutional investors in the last quarter, including Viking Global Investors LP, Winslow Capital Management LLC, Lone Pine Capital LLC, FIL Ltd, Oak Ridge Investments LLC, Principal Financial Group Inc., Principal Financial Group Inc., and Lord Abbett & CO. LLC.
View insider buying and selling activity for Insulet or or view top insider-buying stocks.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PODD stock can currently be purchased for approximately $280.55.

Insulet has a market capitalization of $18.59 billion and generates $904.40 million in revenue each year. The medical instruments supplier earns $6.80 million in net income (profit) each year or $0.10 on an earnings per share basis.

Insulet employs 1,900 workers across the globe.

Insulet was founded in 2000.

The official website for Insulet is www.insulet.com.

Insulet is headquartered at 100 NAGOG PARK, ACTON MA, 01720.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]